CASI Pharmaceuticals, Inc. (NASDAQ:CASI) is reporting second quarter earnings results on Monday 10th August 2020, before market open.
The consensus estimates from Thomson Reuters are loss of $ 0.08 per share from $ 3.75 million in revenue.
For the full year, analysts predict revenues of $ 12.67 million, while looking forward to loss of $ 0.3 per share.
Previous Quarter Performance
CASI Pharmaceuticals, Inc. outlined loss for the first quarter of $ 0.09 per share, from the revenue of $ 3.41 million. The quarterly earnings compared with the same quarter last year. Wall street analysts are predicting, CASI to report 1Q20 loss of $ 0.11 per share from revenue of $ 0.79 million. The bottom line results beat street analysts by $ 0.02 or 18.18 percent, at the same time, top line results outshined analysts by $ 2.62 million or 331.65 percent.
Historical Earnings Performance
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Click Here For More Historical Earnings Of CASI Pharmaceuticals, Inc.
Stock Performance
According to the previous trading day, closing price of CASI was $ 1.89, representing a 64.35 % increase from the 52 week low of $ 1.15 and a 50.52 % decrease over the 52 week high of $ 3.82.
The company has a market capital of $ 234.25 million and is part of the Healthcare sector and Biotechnology industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”CASI” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
CASI Pharmaceuticals, Inc. will be hosting a conference call at 4:30 PM eastern time on 10th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.casipharmaceuticals.com
CASI Pharmaceuticals, Inc., a pharmaceutical company, develops pharmaceutical products and various therapeutics in China, the United States, and internationally. The companys product pipeline includes EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma. Its product pipeline also comprises ZEVALIN, an ibritumomab tiuxetan injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular B-cell non-Hodgkins lymphoma, as well as for the treatment of patients with previously untreated follicular non-Hodgkins lymphoma; and MARQIBO, a microtubule inhibitor to treat adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia.
